Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0902 Fin QTs
BioCentury & Getty Images


Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more  

Sep 3, 2020 | 1:28 AM GMT

Taysha joins IPO queue four months after spinout
Taysha Gene Therapies Inc. proposed to raise up to $100 million in a NASDAQ IPO. Founded in partnership with the University of

Read the full 569 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers